Research Nester released a report titled “Myeloid Blood Cancer Treatment Market: Global Demand Analysis & Opportunity Outlook 2029” which delivers detailed overview of the global myeloid blood cancer treatment market in terms of market segmentation by treatment type, end-user, and region.
Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.
The myeloid blood cancer treatment market is projected to grow with a moderate CAGR during the forecast period, i.e., 2021-2029 on account of the increasing prevalence of myeloid blood cancer and the rising elderly population on a global scale. As per the American Cancer Society, in 2019, the assessed new cases and number of deaths from leukaemia in U.S. were 61,780 and 22,840, respectively.
The market is segmented by treatment type into chemotherapy, immunotherapy, radiotherapy, targeted therapy, stem cell therapy, and others. Among these segments, the targeted therapy segment is anticipated to hold the largest share by the end of 2021 in the myeloid blood cancer treatment market as a result of the higher positive diagnosis rates of targeted therapy than other available treatments.
On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, out of which, the myeloid blood cancer treatment market in the Asia Pacific is projected to grow at the highest CAGR throughout the forecast period. Currently, the market in North America holds the largest share. This can be attributed to the presence of leading healthcare providers in the region, especially in the United States, who are extensively involved in the research and development for innovative cancer treatment procedures.
Request Sample To Learn More About This Report @ https://www.researchnester.com/sample-request-3023
Increasing Prevalence of Myeloid Blood Cancer and Rising Elderly Population on a Global Scale to Drive Market Growth
According to the United Nations, it is estimated that by 2050, every one in six people will be 65 years or older, i.e., 16% of the total world population. Along with this, the number of persons above 80 years or older is also projected to triple by the end of 2050.
Age is one of the most predominant risk factors for any kind of blood cancer. It has been observed that individuals whose age is above 65 years or more possess a high risk of having myeloid blood cancer. Additionally, the rising prevalence of myeloid blood cancer in recent years is also expected to boost the market growth in upcoming years. However, the expensive cost of myeloid blood cancer therapies and stringent regulatory policies on drugs in some regions are some of the factors that are estimated to restrain market growth in the near future.
This report also provides the existing competitive scenario of some of the key players of the global myeloid blood cancer treatment market which includes company profiling of Pfizer Inc. (NYSE: PFE), Bristol Myers Squibb (NYSE: BMY), F. Hoffmann-La Roche AG (SWX: RO), Teva Pharmaceuticals (TLV: TEVA), Sanofi (EPA: SAN), AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), Novartis AG (SWX: NOVN), and Amgen, Inc. (NASDAQ: AMGN). The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global myeloid blood cancer treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Request Sample To Learn More About This Report @ https://www.researchnester.com/sample-request-3023
Replies